Mast Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2015. The supplied filing identifies the registrant as Mast Therapeutics, Inc., not Savara Inc.
Business context
Mast was a clinical-stage biopharmaceutical company with no product sales or significant revenue. Its lead candidate, vepoloxamer, was being developed for sickle cell disease, arterial disease and heart failure. The company was also developing AIR001 for heart failure with preserved ejection fraction (HFpEF).
Financial results and position
| Metric | Q1 2015 | Q1 2014 or prior balance date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.0 million | $4.3 million |
| Selling, general and administrative expense | $3.6 million | $2.3 million |
| Total operating expenses | $9.7 million | $6.8 million |
| Net loss | $9.6 million | $6.4 million |
| Net loss per share | $0.06 | $0.06 |
| Net cash used in operating activities | $7.3 million | $6.3 million |
| Cash and cash equivalents | $27.9 million | $35.8 million at Dec. 31, 2014 |
| Investment securities | $22.0 million | $21.5 million at Dec. 31, 2014 |
| Total assets | $62.7 million | $70.5 million at Dec. 31, 2014 |
| Total liabilities | $12.6 million | $11.8 million at Dec. 31, 2014 |
Cash, cash equivalents and investments totaled $49.9 million at quarter-end. Current assets were $50.6 million and current liabilities $9.2 million. The balance sheet showed a $27,000 long-term lease obligation and a $3.4 million deferred tax liability; the filing reports no material conventional borrowing. Operating margin is not meaningful because the company had no revenue.
Changes versus comparable periods
- R&D expense rose $1.8 million, approximately 41%, mainly from higher EPIC sickle-cell study costs and research-related manufacturing.
- SG&A expense increased $1.3 million, approximately 58%, including higher personnel and consulting costs.
- Net loss increased $3.2 million. Q1 2014 included a $0.5 million bargain-purchase gain from the Aires acquisition, which did not recur.
- Operating cash use increased by about $1.1 million. Cash and cash equivalents declined $7.9 million from year-end, while investment securities increased $0.5 million.
Outlook, risks and notable items
- Management expected existing cash, cash equivalents and investments to fund planned operations for at least 12 months. It forecast 2015 operating expenses of approximately $35–$38 million, excluding share-based compensation.
- The company stated that current resources were not expected to fund development through commercialization; additional equity, debt or collaboration financing would likely be needed. Availability and terms of financing were uncertain.
- EPIC, the pivotal Phase 3 vepoloxamer sickle-cell study, planned to enroll 388 subjects. As of April 20, 2015, 205 had enrolled; top-line results were expected in Q1 2016. These timelines were forward-looking estimates.
- A Phase 2 vepoloxamer study in acute limb ischemia was enrolling about 60 patients, with completion estimated in the second half of 2016. A chronic heart-failure Phase 2 study was planned for Q3 2015.
- AIR001 Phase 2a studies in HFpEF were underway at two institutions; a third was expected later in 2015, with preliminary data anticipated in the second half of 2015. A Phase 2b study depended on positive results.
- Q1 SG&A included $0.4 million of severance and $0.3 million of accelerated share-based compensation following the former president and COO’s February 2015 departure. Total share-based compensation expense was $1.1 million.
- The AIR001 acquired in-process R&D asset was not considered impaired in the February 2015 quantitative test, although its valuation depended on judgmental development and commercial assumptions.
- Key risks included clinical or regulatory failure or delay, patient enrollment, reliance on third-party manufacturers and research providers, uncertain future financing, potential dilution, intellectual-property matters and continued listing requirements. The company reported no material pending litigation and effective disclosure controls.
Investor facts to verify
- Confirm clinical enrollment, study timelines and whether the projected data dates were subsequently achieved.
- Track cash burn against the stated 12-month runway and $35–$38 million 2015 expense estimate; assess funding needs and financing terms.
- Review warrant and option overhang: 79.1 million warrants were outstanding at March 31, 2015, in addition to options, with potential dilution dependent on exercise and other conditions.
- Monitor the assumptions underlying AIR001 and vepoloxamer asset valuations, and any future impairment indicators.
- Confirm the intended issuer: the filing supplied is for Mast Therapeutics, Inc.; it does not identify Savara Inc. as the registrant.